-
-
-
-
-
-
-
Cytokinetics (CYTK) Misses Q1 EPS by 2c
-
-
-
-
-
-
-
Cytokinetics (CYTK) PT Raised to $100 at Mizuho
-
-
-
-
-
-
-
Cytokinetics (CYTK) Reiterated at Overweight by Cantor Fitzgerald: Encouraging Signs
-
-
-
-
-
-
-
Cytokinetics launches MYQORZO for hypertrophic cardiomyopathy in US
-
-
-
-
-
-
-
Here's the list of top biotech stocks to own for 2026
-
-
-
-
-
-
-
Cytokinetics (CYTK) PT Raised at RBC Capital into Aficamten 2026 Launch
-
-
-
-
-
-
-
Cytokinetics (CYTK) October 40 calls and January 55 calls active
-
416,806 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

